Skip Navigation

This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (24)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Bramwell, V. H. C.
Right arrow Articles by Bogues, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bramwell, V. H. C.
Right arrow Articles by Bogues, W.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 6:847-849, 1995
© 1995 European Society for Medical Oncology

research-article

Phase II study of topotecan (NSC 609 699) in patients with recurrent or metastatic soft tissue sarcoma

V. H. C. Bramwell1,, E. A. Eisenhauer2, M. Blackstein3, G. Boos4, M. Knowling5, J. Jolivet6 and W. Bogues2

1London Regional Cancer Centre London, Ontario
2National Cancer Institute of Canada Clinical Trials Group Kingston
3Mount Sinai Hospital Toronto, Ontario
4McGill University, Montreal Quebec
5British Columbia Cancer Agency, Vancouver British Columbia
6'Hospital Notre-Dame, Montreal Quebec, Canada

Correspondence to: Dr. Vivien Bramwell London Regional Cancer Centre 790 Commissioners Road East London, Ontario N6A, 4L6 Canada

Background: New drugs are needed for treatment of un-resectable or metastatic soft tissue sarcoma. Topotecan, a semisynthetic derivative of the alkaloid, camptothecin, exerts its cytotoxic effect through inhibition of topoisomerase I

Patients and methods: Thirty-two adult patients with locally advanced or metastatic soft tissue sarcoma entered this phase II study of topotecan, administered at 1.5 mg/m2/ day IV x 5 days every 3 weeks. All had measurable disease and none had received previous chemotherapy

Results: There were 3 partial responses (10.3%; 95% CI 2.2–27.4%) in 29 evaluable patients. Grade 3 or 4 neutropenia occurred in 25 patients, and there was a 17% incidence of infection/neutropenic fever leading to one toxic death

Conclusions: Topotecan, in this dose and schedule, has low activity in adult soft tissue sarcoma

soft tissue sarcoma, advanced disease, new drugs, topotecan


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
R. Garcia-Carbonero, J.G. Supko, J. Manola, M.V. Seiden, D. Harmon, D.P. Ryan, M.T. Quigley, P. Merriam, J. Canniff, G. Goss, et al.
Phase II and Pharmacokinetic Study of Ecteinascidin 743 in Patients With Progressive Sarcomas of Soft Tissues Refractory to Chemotherapy
J. Clin. Oncol., April 15, 2004; 22(8): 1480 - 1490.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
V. H. C. Bramwell, D. Morris, D. S. Ernst, I. Hings, M. Blackstein, P. M. Venner, E. I. Ette, M. W. Harding, A. Waxman, and G. D. Demetri
Safety and Efficacy of the Multidrug-Resistance Inhibitor Biricodar (VX-710) with Concurrent Doxorubicin in Patients with Anthracycline-resistant Advanced Soft Tissue Sarcoma
Clin. Cancer Res., February 1, 2002; 8(2): 383 - 393.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Delaloge, A. Yovine, A. Taamma, M. Riofrio, E. Brain, E. Raymond, P. Cottu, F. Goldwasser, J. Jimeno, J. L. Misset, et al.
Ecteinascidin-743: A Marine-Derived Compound in Advanced, Pretreated Sarcoma Patients--Preliminary Evidence of Activity
J. Clin. Oncol., March 1, 2001; 19(5): 1248 - 1255.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
J.-F. Héron
Topotecan: An Oncologist's View
Oncologist, December 1, 1998; 3(6): 390 - 402.
[Abstract] [Full Text]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.